Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43 results about "Atp level" patented technology

55 ATP Levels in RBCs and T Cells and the Effects of Age on Mitochondrial Potential respectively. For red cells, the average level of ATP per 10 6 cells was 360 ± 64 nM. For T cells, the average level of ATP was 8500 ± 1400 nM per 106 cells. Pathological conditions may have an influence on the ATP content.

Nonsymbiotic plant hemoglobins to maintain cell energy status

Nonsymbiotic hemoglobins are broadly present across evolution; however, the function of these proteins is unknown. Cultured maize cells have been transformed to constitutively express a barley hemoglobin gene in either the sense (HB+) or antisense (HB−) orientation. Hemoglobin protein in the transformed cell lines was correspondingly higher or lower than in wild type cells under normal atmospheric conditions. Limiting oxygen availability, by placing the cells in a nitrogen atmosphere for 12 hours, had little effect on the energy status of cells constitutively expressing hemoglobin, but had a pronounced effect on both wild type and HB− cells, where ATP levels declined by 27% and 61% respectively. Energy charge was relatively unaffected by the treatment in HB+ and wild type cells, but was reduced from 0.91 to 0.73 in HB− cells suggesting that the latter were incapable of maintaining their energy status under the low oxygen regime. Similar results were observed with P. aeruginosa cells transformed with an Hb expression vector. It is suggested that nonsymbiotic hemoglobins act to maintain the energy status of cells in low oxygen environments and that they accomplish this effect by promoting glycolytic flux through NADH oxidation, resulting in increased substrate level phosphorylation. Nonsymbiotic hemoglobins are likely ancestors of an early form of hemoglobin that sequestered oxygen in low oxygen environments, providing a source of oxygen to oxidize NADH to provide ATP for cell growth and development. This in turn suggests that cells containing increased levels of Hb protein will survive longer under low oxygen tension or high energy demand.
Owner:UNIVERSITY OF MANITOBA

Technology for producing glutathione by fermenting saccharomyces cerevisiae

The invention discloses a technology for producing glutathione by fermenting saccharomyces cerevisiae and belongs to the field of industrial microbial fermentation. The technology for producing glutathione by fermenting saccharomyces cerevisiae comprises the following steps: utilizing an improved O-media fermentation medium to ferment for 16h, and then adding molasses and corn liquor at constant speed of 1.5g/L/h and 0.4g/L/h; after the cell density reaches a certain degree, adding a certain amount of KMnO4 slow-released grains and sodium citrate into the fermentation liquor; fermenting for 120h so that the cell wet weight in the fermentation liquor reaches up to 121.4g/L and the GSH accumulated volume reaches up to 5.78g/L. According to the invention, the cell density of the fermentation liquor is promoted through the improvement for the O-media fermentation medium and the flow adding of the molasses and corn liquor; the oxidative stress for yeast cells is maintained and meanwhile the influence thereof on the yeast growth is relieved through the addition of oxidized stimulant KMnO4 slow-released grains; intracellular ATP level is improved through the addition of the energy auxiliary matter sodium citrate, and finally, the accumulated volume of glutathione is obviously improved and the production cost is lowered.
Owner:盐城仁越生物科技有限公司

Method for testing the severtiy of an illness

InactiveUS20130071866A1Accurately deducedHigh risk of mortalityMicrobiological testing/measurementDisease diagnosisSeverity levelKetone
An object of the present invention is directed to a method for assaying the severity of an illness in real time and is to provide a testing method capable of assessing the severity of an illness in more detail than the conventional APACHE II and SOFA scores. The established method can accurately measure an ATP level in a sample, thereby accurately and quickly deducing the “state of intracellular energy required for living organisms” from the ATP level, and by extension, determining the severity of an illness. The present invention further provides a novel biomarker ATP-lactate energy risk score (A-LES) value that is capable of determining the severity of an illness by the reevaluation, with the ATP concentration as an index (specifically, on the basis of a lactic acid level (mM)/ATP concentration (mM) ratio), of the level of lactic acid that accumulates in the sample due to the breakdown of in vivo metabolic balance accompanied by the increased severity of the illness. The present invention also provides a novel biomarker ATP-ketone energy risk score (A-KES) value that is capable of determining the severity of an illness by the reevaluation of a ketone body level in the sample with the ATP concentration as an index (specifically, on the basis of a ketone body level (mM)/ATP concentration (mM) ratio).
Owner:UNIVERSITY OF TOKUSHIMA

Preparation method of compound PGHG in medicine for treating parkinson's disease

The invention discloses a preparation method of a compound PGHG in a medicine for treating parkinson's disease. The method comprises the following steps: performing ultrasonic extraction on Penthorumchinense Pursh. stem dry powder by using 70 percent of ethanol (1: 25), sequentially performing extraction by using petroleum ether and ethyl acetate to obtain extracting solutions; performing decompressing concentration and lyophilization on the extracting solutions to obtain Penthorum chinense Pursh. polyphenol fragments (PSE); separating the PSE through high-speed countercurrent chromatographyto obtain flow fractions A and B; further purifying the flow fraction A by adopting a preparative HPLC (High Performance Liquid Chromatography); manually collecting effluent liquid according to a chromatographic peak; performing decompressing concentration to obtain a monomer compound of which the purity is up to 99 percent; and the monomer compound is identified as PGHG through mass spectrometryand nuclear magnetic resonance spectroscopy. Due to the PSE and the PGHG, reduction of ATP level of 6-hydroxydopamine induced SH-SY5Y cells can be obviously suppressed, and the cell activity is improved. The PGHG can modulate and control expression of apoptosis protein and inflammatory protein through activating Nrf2/HO-1 antioxidant pathway, and neuroprotection has an obvious effect on preventionand treatment of the parkinson's disease.
Owner:SICHUAN UNIV

Preparation method of ganoderma spore composition for treating Alzheimer disease

The invention belongs to the technical field of ganoderma spore compositions, and discloses a preparation method of a ganoderma spore composition for treating an Alzheimer disease. The preparation method comprises the following steps of picking fresh ganoderma spores, removing impurities and no-medicinal parts of the fresh ganoderma spores, the cleaning the fresh ganoderma spores, removing dust onthe upper parts of the ganoderma spores, and drying the fresh ganoderma spores; putting the dried ganoderma spores into a low temperature supersonic speed airflow energy grender to conduct grinding treatment, and ganoderma spore powder is formed; and taking the dried ganoderma spore powder, and through a 120 mesh screen, removing impurities. According to the ganoderma spore composition, the production technology is simple, operation is convenient, the ROS levels in blood platelets of an AD patient can be reduced by taking the ganoderma spore composition, plasma Abeta42 of the AD patient can be stabilized at a certain level, influences on the ATP levels of the blood platelets, mitochondrion COX activity of the blood platelets and the LEH level of the plasma of the AD patient are not generated, and swelling of mitochondrial of the blood platelets of the AD patient can be relaxed certainly.
Owner:钟志强
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products